02:54 AM EDT, 10/08/2026 (MT Newswires) -- Bayer's (BAYN.F) supplemental new drug application for finerenone, a potential treatment for non-diabetic patients with chronic kidney disease, was accepted by the US Food and Drug Administration. The acceptance was based on the German life science company's phase 3 Find-CKD study, which demonstrated that finerenone significantly delayed disease progression and also reduced cardiovascular-kidney events, according to a Thursday release.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.